Highly self motivated and productive Research Scientist with 20 years of academic and pharmaceutical laboratory experience and over 10 years of line management responsibility. Demonstrated ability in building and leading highly productive and diverse teams of scientists. Extensive experience in collaborating with cross functional teams to deliver timely results Specialties:Lipid biochemistry, lipid signaling, signal transduction and pathway analysis, mitochondrial biology, mRNA and microRNA profiling, therapeutic target identification and validation, human adipose-derived stem cell biology and mouse muscle stem cell biology

President @ Lead the scientific and operating efforts of the Company, managing all departments as well as all corporate and scientific partnerships for research and development. Design and implement a development plan within a budget, timeline and milestones to achieve IND, FDA and clinical goal to lead the first product to market. From February 2012 to Present (3 years 10 months) Chapel Hill, NCScientific Director @ G-Zero is both a therapeutic and diagnostic company. We are currently working on a proprietary small molecule approach to protect the bone marrow from radiation or chemotherapy and development and commercialization of a blood biomarker for "molecular aging" From May 2009 to September 2012 (3 years 5 months) Manager, Cell Technology Group @ Collaborating with Amy Wager’s laboratory of the Harvard Stem Cell Institute to characterize mechanisms regulating stem cell self renewal and differentiation of mouse skeletal muscle progenitor cells. Utilizing genomic, biochemical and chemical approaches to understanding pathways regulating the aging process in mouse SMPs. From 2008 to 2009 (1 year) Manager, Energy Homeostasis, Metabolic Discovery Technology Group @ • Successfully led team of scientists in the characterization and utilization of Human adipose-derived stem cells for drug discovery • Discovery of novel compounds regulating mitochondrial function and biogenesis. • Identification and characterization of microRNAs which regulate SirT1 protein levels, NFkB activation and inflammation in Human adipose-derived stem cells. • Identification of novel targets and compounds for inhibiting adipogenesis/lipogenesis. From 2006 to 2008 (2 years) Manager, US Quantitative Expression @ • Led groups of scientists in RTP and Philadelphia to support gene expression profiling needs for GSK • Successfully managed operational and capital budgets, resource allocation and a dynamic project portfolio supporting multiple therapeutic areas • Led cross functional teams to design and implement bioinformatics and statistical analysis solutions for gene expression data and pathway analysis • Implemented cost efficiency through assay miniaturization and automation. From 2004 to 2006 (2 years) Manager, Quantitative Expression @ • Managed the Gene Expression Profiling core facility in RTP including responsibility for operational and capital budgets and project portfolio. • Expanded the Gene Expression Profiling core facility capabilities to support all of GSK Research • Developed novel applications of real time PCR to support various aspects of drug discovery • Designed mRNA expression databases which allowed expression profiles to be queried by all of GSK Research From 2001 to 2004 (3 years) Research Investigator I @ • Project leader for discovery of neutral sphingomyelinase inhibitors and Edg1 receptor antagonists. • Evaluated and implemented the use of real time PCR (TaqMan). • Created a core facility to support mRNA expression analysis for GlaxoWellcome. • Created a Human Tissue Bank to support the needs of the gene expression profiling core. From 1996 to 2001 (5 years)

PhD, Biochemistry @ Wake Forest University From 1987 to 1993 BS/BA, Biology, Chemistry @ Western Carolina University From 1982 to 1987 Jay Strum is skilled in: Drug Discovery, Lipid, Stem Cells, Assay Development, Cell Biology, Molecular Biology, Lifesciences, Lipids, Laboratory, Biotechnology, Biochemistry, Genomics, Protein Chemistry, Biomarker Discovery, Biomarkers, FDA, Signal Transduction, Cell, Medical Devices, Pharmaceutical Industry, Oncology, qPCR, Biopharmaceuticals, Bioinformatics, Clinical Research, Cross-functional Team..., Cell Culture, HPLC, Maintaining A Positive..., Commercialization, Metabolism, Validation, IND, Automation, Immunology, Drug Development, Clinical Development, R&D, Clinical Trials, Life Sciences, Entrepreneurship, Translational Medicine